BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

...since April 2017 include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir...
BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

...since April 2017 include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

...approved since April. These include Daklinza daclatasvir and Sunvepra asunaprevir from Bristol-Myers Squibb Co.; Viekirax ombitasvir/paritaprevir/ritonavir...
...in China. According to ClinicalTrials.gov, Phase III studies in China of BMS’s Daklinza and AbbVie’s Technivie...
...did not provide details on the genotypes for which Olysio was approved. AbbVie’s regimen of Viekirax...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...Selected 3Q approvals. Selected 3Q regulatory setbacks. Company Approval AbbVie Inc. (NYSE:ABBV) China approves Viekirax ombitasvir/paritaprevir/ritonavir...
BioCentury | Sep 29, 2017
Clinical News

China approves HCV drugs from Gilead and AbbVie

...the U.S., EU and 79 other countries. Separately, AbbVie Inc. (NYSE:ABBV) told BioCentury that Viekirax ombitasvir/paritaprevir/ritonavir...
...including those without cirrhosis or with compensated cirrhosis. AbbVie said negotiations for reimbursement are ongoing. Viekirax...
...Ill. Product: Sovaldi sofosbuvir (GS-7977) (formerly PSI-7977); Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir (ABT-333) Business: Infectious Chris Lieu dasabuvir Exviera ombitasvir/paritaprevir/ritonavir sofosbuvir Sovaldi Viekirax AbbVie...
BioCentury | Sep 25, 2017
Company News

Gilead's Sovaldi gets Chinese approval

...BioCentury Extra, March 3) . Also on Monday, AbbVie Inc. (NYSE:ABBV) told BioCentury that Viekirax ombitasvir/paritaprevir/ritonavir...
...time for publication regarding the date of the approval or plans for reimbursement in China. Viekirax...
BioCentury | May 19, 2017
Strategy

Contracting 2.0

...in the battle over the Sovaldi follow-ons: pitting the less convenient, lower cost Viekira Pak ombitasvir/paritaprevir/ritonavir...
BioCentury | Jan 27, 2017
Clinical News

Glecaprevir/pibrentasvir: Ph III CERTAIN-1 data

...for 8 weeks met the primary endpoint of non-inferiority to a 12-week regimen of Viekirax ombitasvir/paritaprevir/ritonavir...
...variant (n=106) and 100% in patients with the Y93H HCV variant (n=23) vs. 100% for Viekirax...
...product this quarter. Enanta and AbbVie discovered glecaprevir under a 2006 deal. AbbVie developed pibrentasvir. Viekirax...
BioCentury | Dec 16, 2016
Company News

Harvoni sales and marketing update

...pricing war, Harvoni had been kept out in favor of exclusive access for Viekira Pak ombitasvir/paritaprevir/ritonavir...
Items per page:
1 - 10 of 70